Literature DB >> 27354222

Stroke in Duchenne Muscular Dystrophy: A Retrospective Longitudinal Study in 54 Patients.

Martin Winterholler1, Christian Holländer2, Frank Kerling2, Irina Weber2, Sven Dittrich2, Matthias Türk2, Rolf Schröder2.   

Abstract

BACKGROUND AND
PURPOSE: Duchenne muscular dystrophy (DMD) is the most frequent skeletal muscle myopathy. Nearly all patients develop cardiomyopathy in their second decade of life. The purpose of this study was to evaluate the frequency, cause, and outcome of stroke in a German cohort of patients with DMD.
METHODS: Retrospective analysis of medical records of 54 DMD patients, who lived in a regional facility for handicapped people (Wichernhaus Altdorf, Germany) between 1963 and 2013.
RESULTS: Fifty-four DMD patients were followed up for 7.4 years on average. Mean age at admission and discharge from the long-term care facility or death were 11.4 and 18.8 years, respectively. Covering a total observation period of 400 patient-years, we identified 4 DMD patients with juvenile arterial ischemic strokes. Off-label systemic thrombolysis in 2 patients resulted in a nearly complete regression of stroke-related symptoms, but 1 patient died of septic pneumonia and cardiac failure 24 days after thrombolysis therapy. In the other 2 patients, who had their ischemic strokes in 1994 and 1998, severe infarction-related symptoms persisted, and 1 patient died 13 days later. DMD-associated cardiomyopathy without evidence of atrial fibrillation was the only risk factor for ischemic stroke in all patients.
CONCLUSIONS: This study indicates an increased risk for ischemic strokes in DMD patients. Regular cardiological assessment of all DMD patients is mandatory to evaluate the individual risk profile for cardioembolic events and to adapt therapeutic strategies.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  Duchenne muscular dystrophy; cardiomyopathy; dystrophin; stroke; thrombolytic therapy

Mesh:

Year:  2016        PMID: 27354222     DOI: 10.1161/STROKEAHA.116.013678

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction.

Authors:  Mackenzie Hagan; Muhammad Ashraf; Il-Man Kim; Neal L Weintraub; Yaoliang Tang
Journal:  Med Hypotheses       Date:  2017-11-23       Impact factor: 1.538

2.  Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey.

Authors:  David C Schorling; Cornelia K Müller; Astrid Pechmann; Sabine Borell; Thorsten Langer; Simone Thiele; Maggie C Walter; Barbara Zieger; Janbernd Kirschner
Journal:  Acta Myol       Date:  2020-03-01

3.  Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis.

Authors:  Suning Chen; Mao Sun; Xianghui Zhao; Zhifu Yang; Wenxing Liu; Jinyi Cao; Yi Qiao; Xiaoxing Luo; Aidong Wen
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

4.  Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.

Authors:  Sven Dittrich; Erika Graf; Regina Trollmann; Ulrich Neudorf; Ulrike Schara; Antje Heilmann; Maja von der Hagen; Brigitte Stiller; Janbernd Kirschner; Robert Dalla Pozza; Wolfgang Müller-Felber; Katja Weiss; Katja von Au; Markus Khalil; Reinald Motz; Christoph Korenke; Martina Lange; Ekkehard Wilichowski; Joseph Pattathu; Friedrich Ebinger; Nicola Wiechmann; Rolf Schröder
Journal:  Orphanet J Rare Dis       Date:  2019-05-10       Impact factor: 4.123

5.  Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study.

Authors:  Edyta Blaszczyk; Carolin Lim; Peter Kellman; Luisa Schmacht; Jan Gröschel; Simone Spuler; Jeanette Schulz-Menger
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-08       Impact factor: 5.364

6.  One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure.

Authors:  Lisa Wahlgren; Anna-Karin Kroksmark; Mar Tulinius; Kalliopi Sofou
Journal:  Eur J Epidemiol       Date:  2021-11-21       Impact factor: 8.082

7.  Melatonin protects against focal cerebral ischemia-reperfusion injury in diabetic mice by ameliorating mitochondrial impairments: involvement of the Akt-SIRT3-SOD2 signaling pathway.

Authors:  Lian Liu; Quan Cao; Wenwei Gao; Bingyu Li; Zhongyuan Xia; Bo Zhao
Journal:  Aging (Albany NY)       Date:  2021-06-11       Impact factor: 5.682

8.  Mechanical thrombectomy in a young stroke patient with Duchenne muscular dystrophy.

Authors:  Charlotte Spicher; Ruth Schneider; Peter Mönnings; Christiane Schneider-Gold; Dennis Kallenberg; Bilal Cevik; Carsten Lukas; Ralf Gold; Christos Krogias
Journal:  Ther Adv Neurol Disord       Date:  2018-03-01       Impact factor: 6.570

9.  Social stress is lethal in the mdx model of Duchenne muscular dystrophy.

Authors:  Maria Razzoli; Angus Lindsay; Michelle L Law; Christopher M Chamberlain; William M Southern; Madeleine Berg; John Osborn; William C Engeland; Joseph M Metzger; James M Ervasti; Alessandro Bartolomucci
Journal:  EBioMedicine       Date:  2020-03-16       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.